Stockreport

Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update [Yahoo! Finance]

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF an ACR50 of ~50% at six months in patients after failure of two targeted therapies and expects to interact with the FDA and share RA data on =15 patients in the first ha [Read more]